Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -46.7%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $56M | $27M | $49M | — | — | — | — | — | — |
| Enterprise Value | $87M | $58M | $70M | — | — | — | — | — | — |
| P/E Ratio → | -0.96 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.57 | 0.27 | 0.33 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.7% | -46.7% | -554.9% | — | — | -12.5% | -43.0% | -65.4% | -50.0% |
| ROA | -32.0% | -32.0% | -38.9% | -47.8% | -48.2% | -8.6% | -39.6% | -56.3% | -42.0% |
| ROIC | -31.6% | -31.6% | -475.9% | — | — | -16.3% | -46.8% | -66.4% | -52.5% |
| ROCE | -37.1% | -37.1% | -46.0% | -57.8% | -51.9% | -9.1% | -44.1% | -64.2% | -46.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.50 | 0.50 | 0.32 | — | — | — | 0.02 | 0.05 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.32 | 0.14 | — | — | — | -0.31 | -0.20 | -0.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.74 | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Quick Ratio | 8.74 | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Cash Ratio | 8.58 | 8.58 | 18.70 | 12.90 | 8.63 | 18.89 | 17.37 | 7.54 | 8.35 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $22M | $17M | $22M | $22M | $22M | $44M | $27M | $11M |
Critical Clinical Funding Gap
Based on recent financial data, Boundless Bio trades at a price-to-book ratio of 0.58, which suggests that the market is heavily discounting the company's asset base relative to its peers in the precision oncology space, likely due to the absence of revenue and significant clinical-stage execution risks.
The low P/B multiple relative to peers like Immunovant or Kymera Therapeutics indicates that investors are assigning little value to the company's proprietary Spyglass platform or its clinical pipeline. This valuation gap suggests that the market may be pricing in a high probability of future equity dilution or a failure to reach meaningful clinical milestones.
According to quarterly financial statements, Boundless Bio's ROIC has remained consistently negative, reaching -8.8% in 2026Q1, which reflects the company's inability to generate returns on its invested capital while it continues to prioritize high-cost R&D activities over commercialization or operational efficiency.
The persistent negative ROIC trend highlights the structural challenge of a pre-revenue biotech firm where capital is consumed by clinical trials rather than deployed into productive assets. Investors should monitor whether the company can improve these returns as it moves toward potential data readouts, though current trends suggest a continued decay in capital efficiency.
As reported in recent SEC filings, the company's current ratio has compressed significantly from 22.15 in 2025Q1 to 9.87 in 2026Q1, signaling a rapid depletion of liquid assets that leaves the firm increasingly vulnerable to operational disruptions or unexpected delays in its clinical trial programs.
While a current ratio of 9.87 appears high in isolation, it must be interpreted in the context of a company with no revenue and high fixed cash burn. This decline suggests that the company's liquidity buffer is eroding faster than its clinical progress, which may necessitate a near-term capital raise to maintain operations.
Based on a comparison with peers like IDEAYA Biosciences and Kymera Therapeutics, Boundless Bio's negative profitability and lack of revenue place it at the lower end of the valuation spectrum, reflecting a structural lag in clinical maturity compared to firms with more advanced, de-risked oncology pipelines.
The gap between Boundless Bio and its peers appears to be driven by the company's earlier-stage status and the specific, unproven nature of its ecDNA-targeting approach. Unlike peers that have established clinical proof-of-concept, Boundless Bio remains in a high-risk phase where its financial ratios are dominated by development costs rather than market-validated therapeutic success.
Investors frequently misapply the price-to-book ratio to Boundless Bio, failing to recognize that in a clinical-stage biotech, book value is often dominated by capitalized R&D or equipment rather than liquid assets, which obscures the true risk of the company's cash-burning business model.
The P/B ratio is a poor proxy for value here because it does not account for the binary nature of clinical trial outcomes or the rapid depletion of cash. A more appropriate metric for this business model would be the cash runway or the enterprise value relative to the number of clinical programs, as these better reflect the company's actual survival prospects.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BOLD stock.
Boundless Bio, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Boundless Bio, Inc.'s return on equity (ROE) is -46.7%. The historical average is -43.5%.
Based on historical data, Boundless Bio, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.